Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
mouse monoclonal antibody used toimage the extent of prostate cancer.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word capromab.
Examples
-
The abstracts John Theurer Cancer Center will present focus on the following topics: laparoscopic adrenalectomy (horseshoe kidney), hypogonadal patients receiving clomiphene citrate or anastrozole for infertility, robot-assisted radical prostatectomy and CT-fused indium-111 capromab pendetide immunoscintigraphy in management of recurrent prostate cancer.
-
EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively ...
THE MEDICAL NEWS Editors 2010
-
EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively ...
THE MEDICAL NEWS 2009
-
This research focused on the use of PROSTASCINT® (capromab pendetide), a monoclonal antibody, linked to the radioisotope Indium-111 that specifically targets prostate-specific membrane antigen (PSMA), and is used in the evaluation of patients at risk for metastatic prostate cancer.
Medindia Health News 2009
-
PROSTASCINT® (capromab pendetide) is indicated as a diagnostic imaging agent in newly diagnosed patients with biopsy proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation and who are thought to be at high risk for pelvic lymph node metastases.
Medindia Health News 2009
-
The cohort included 22 patients, all of whom were thought to have a clinical diagnosis of localized prostate cancer, however had evidence of lymph node involvement on the SPECT/CT In-111 capromab pendetide images.
Medindia Health News 2009
-
A significant finding from this long-term follow-up study is that the presence of metastatic disease in the lymph nodes based on SPECT/CT imaging with PROSTASCINT In-111 capromab pendetide was found to be an independent and significant predictor of biochemical failure for the intermediate risk patients by both bDFS criteria.
Medindia Health News 2009
-
Nov. 4 EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday,
Medindia Health News 2009
-
An abstract entitled "Long-term outcomes following IGRT for localized prostate cancer: dose escalation to SPECT/CT determined biologic target volumes and the bDFS predictive value of capromab pendetide" was presented during podium session at ASTRO's annual meeting.
Medindia Health News 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.